North Carolina Headlines

DelveInsight’s, “Eczema Pipeline Insights 2026” Report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Eczema Pipeline @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight

Key Takeaways from the Eczema Pipeline Report

• In June 2026- Apollo Therapeutics Ltd initiated a phase 2b, multicenter, randomized, double-blind, placebo-controlled study. This study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.
• In June 2026- Amgen conducted a phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon).
• In June 2026- Organon and Co. announced a Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
• In June 2026- Shaperon highlighted a Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis. Part 1 is a dose-escalation part of HY209gel using lower doses of HY209gel (0.5% and 1%) with escalation (HY209gel 2% and 4%) to evaluate the pharmacokinetics(PK), safety, and tolerability of HY209gel treatment. Escalation to the next dose level will be decided by the Safety Monitoring Committee(SMC) that will review all available safety data of the planned dose level within the timeline specified on SMC charter after all enrolled subjects of each cohort complete 2-week treatment and determine the escalation to the next dose to be safe.
• DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
• The leading Eczema Companies such as Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Promising Eczema Pipeline Therapies such as alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.

Stay ahead with the most recent pipeline outlook for Eczema @ Eczema Treatment Drugs

The Eczema Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Eczema Pipeline Report also highlights the unmet needs with respect to the Eczema.

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the “”itch that rashes”” due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults.

Eczema Emerging Drugs Profile

• Amlitelimab: Kymab

Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

• BX 005: BiomX

BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma

LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

The Eczema Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Eczema with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eczema Treatment.
• Eczema Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Eczema Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eczema market

Explore groundbreaking therapies and clinical trials in the Eczema Pipeline @ New Eczema Drugs

Eczema Companies

Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.

Eczema Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Eczema Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn about new Eczema Drugs and developments with DelveInsight’s expert analysis @ Eczema Market Drivers and Barriers

Scope of the Eczema Pipeline Report

• Coverage- Global
• Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
• Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.
• Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth Eczema Pipeline Report today! @ Eczema Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Eczema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eczema– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Amlitelimab: Kymab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Eczema Key Companies
21. Eczema Key Products
22. Eczema- Unmet Needs
23. Eczema- Market Drivers and Barriers
24. Eczema- Future Perspectives and Conclusion
25. Eczema Analyst Views
26. Eczema Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/eczema-pipeline-insight